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ABSTRACT
Post-liver transplantation tumor recurrence is a major challenge for 
hepatocellular carcinoma (HCC) recipients. We aimed to identify early-phase 
circulating microRNAs after liver transplantation for predicting tumor recurrence 
and survival of HCC recipients. Circulating microRNA profiles at early-phase (2-hour 
after portal vein reperfusion) after liver transplantation were compared between HCC 
recipients with (n=4) and without tumor recurrence (n=8) by microarray analyses. 
Candidate microRNAs were validated in 62 HCC recipients by quantitative RT-PCR. The 
prognostic values of microRNAs for tumor recurrence and survival were examined. 
Simulated in vitro ischemia-reperfusion injury models were employed to characterize 
the possible mechanism of up-regulation of circulating microRNAs. Our results showed 
that up-regulation of circulating miR-148a, miR-1246 or miR-1290 at early-phase was 
significantly associated with HCC recurrence after liver transplantation. Among them, 
miR-148a (p=0.030) and miR-1246 (p=0.009) were significant predictors of HCC 
recurrence. MiR-1246 was an independent predictor of overall (p=0.023) and disease-
free survival (p=0.020) of HCC recipients. The level of early-phase circulating miR-
1246 was positively correlated with serum AST and ALT levels in HCC recipients after 
liver transplantation. The expression of hepatic miR-1246 was positively correlated 
with TNFα mRNA. In vitro experiments indicated that injury-induced activation and 
differentiation of macrophages significantly elevated the expression and secretion of 
miR-1246. In conclusion, early-phase circulating miR-1246 is an indicator of hepatic 
injury and a novel prognostic biomarker for tumor recurrence and survival of HCC 
recipients after liver transplantation.
INTRODUCTION
Liver transplantation is regarded as the best curative 
treatment for early stage hepatocellular carcinoma (HCC) 
patients under stringent selection criteria [1]. Shortage of 
liver graft is the main problem for implementing deceased 
donor liver transplantation (DDLT) [2]. The advance of 
living donor liver transplantation (LDLT) largely increases 
the source of liver graft accompanying with comparable 
clinical outcome to DDLT [2]. However, one of the 
major challenges facing LDLT for HCC recipients is a 
higher risk of tumor recurrence compared to DDLT [2, 
3]. Our previous studies have demonstrated that severe 
ischemia-reperfusion injury (IRI) at early-phase after liver 
transplantation not only promotes tumor growth but also 
provides favorable environment for tumor progression 
and invasion [2, 4, 5]. Therefore, we hypothesized that 
late-phase tumor recurrence of HCC recipients after liver 
transplantation could be predictable at early-phase after 
liver transplantation.
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MicroRNAs (miRNA) are small, approximately 
20-30 nucleotides, single stranded non-coding molecules 
function at the post-transcriptional level. miRNAs suppress 
the expression of their target mRNAs by degradation of 
mRNAs or inhibition of translation process [6]. Increasing 
evidences have indicated that microRNAs play important 
regulatory roles in hepatic injury and liver cancer [7, 8]. In 
addition to miRNAs are extremely stable molecules, they 
are useful biomarkers for assessment of hepatic injury and 
diagnosis as well as prognosis of liver diseases in liver 
transplantation [8–10]. In the aspect of tumor recurrence 
after liver transplantation, many studies have discovered 
pre-transplantation miRNAs linking to tumor recurrence. 
For examples, deregulation of single microRNA or a 
group of microRNAs in pre-transplantation HCC tissues 
can predict tumor recurrence and survival of patients 
after liver transplantation [11–13]. Down-regulation of 
pre-transplantation serum exosomal miR-718 in HCC is 
significantly associated with post-transplantation HCC 
recurrence [14]. So far, post-transplantation microRNAs 
linking to tumor recurrence are unknown.
In this study, we applied miRNA microarray analysis 
to identify early-phase circulating miRNAs aiming to 
predict HCC recurrence and survival of HCC recipients 
after liver transplantation. We also used simulated IRI-
related in vitro models to explore the possible reasons 
of alteration of miRNAs during early-phase of liver 
transplantation.
RESULTS
Identification of early-phase circulating miRNAs 
indicating late-phase HCC recurrence after liver 
transplantation
In microRNA microarray analysis, after 
normalization with the expression level of miRNAs in 
healthy donors, 14 significantly upregulated miRNAs 
were identified in recurrent recipients at a false discovery 
rate (FDR) of 0% compared to non-recurrent recipients 
(Figure 1A). There was no significantly down-regulated 
miRNA identified in recurrent recipients based on these 
criteria. Cluster analysis revealed that the expression 
level of these 14 miRNAs in recurrent recipients were 
relatively higher than non-recurrent recipients (Figure 1B). 
Statistical analysis showed that the expressions of 10 out 
of 14 miRNAs in recurrent recipients were significantly 
higher than in non-recurrent recipients (Figure 1C).
In the validation study, comparing to the expression 
level of miRNAs of healthy donors, 10 miRNAs 
exhibited significant up-regulation in early-phase plasma 
of all recipients after liver transplantation (Figure 2A). 
Importantly, significant upregulation of miR-148a 
(p=0.010), miR-1246 (p=0.004) or miR-1290 (p=0.031) 
was detected in HCC recipients with HCC recurrence 
after liver transplantation compared to that without tumor 
recurrence (Figure 2B), suggesting that alteration of these 
early-phase circulating miRNAs might be linking to late 
phase HCC recurrence after liver transplantation.
Early-phase circulating miRNAs predicted 
tumor recurrence and survival of HCC 
recipients after liver transplantation
The High expression group (High group) and the 
Low expression group (Low group) for each miRNA 
were determined using optimal cut-off value from Youden 
index analysis (Supplementary Table S1). Because the 
expression level of early-phase circulating miR-148a, 
miR-1246, or miR-1290 was significantly upregulated 
in recipients with HCC recurrence, we further examined 
the prediction value of these miRNAs (High group versus 
Low group) for tumor recurrence by ROC analysis. 
Among them, miR-148a [AUC=0.727 (95%CI: 0.570–
0.885); Sensitivity=88.9%; Specificity=56.6%; p=0.030, 
Figure 3A] and miR-1246 [AUC=0.775 (95%CI: 
0.626–0.923); Sensitivity=88.9%; Specificity=66.0%; 
p=0.009, Figure 3B] could significantly predict HCC 
recurrence after liver transplantation, while miR-1290 
(Figure 3C) could not reach statistical significance (Table 
1). Combination of miR-148a and miR-1246 could 
reach higher prediction accuracy [AUC=0.841 (95%CI: 
0.704–0.978); Sensitivity=88.9%; Specificity=79.2%; 
p=0.001] (Table 1 and Figure 3D). Moreover, in this 
patient cohort, combination of miR-148a and miR-1246 
exhibited the better prediction accuracy than other pre-
transplant factors including Milan criteria, UCSF criteria 
and pTNM stage (Table 1). The above data suggested that 
early-phase circulating miR-148a and miR-1246 were 
potential prognostic biomarkers for predicting post-liver 
transplantation HCC recurrence.
High level of miR-122, miR-148a, miR-192, miR-
215, miR-1246 or miR-1290 was significantly associated 
with poor overall and disease-free survival of HCC 
recipients after liver transplantation (Figure 4, Table 2). 
Univariate Cox regression analysis revealed that 5 miRNAs 
(miR-122, miR-148a, miR-192, miR-1246 and miR-1290) 
were significant predictors for predicting overall survival 
of HCC recipients, 6 miRNAs (miR-122, miR-148a, miR-
192, miR-215, miR-1246 and miR-1290) were significant 
predictors for predicting disease-free survival of HCC 
recipients (Table 3). No commonly used clinical factor 
was significant predictor in predicting overall or disease-
free survival of HCC recipients after liver transplantation 
(Table 3). Multivariate Cox regression analysis showed that 
miR-1246 was the only significant variable in predicting 
both overall survival (HR=10.24, p=0.023) and disease-
free survival (HR=10.12, p=0.020) (Table 3) of HCC 
recipients after liver transplantation. Therefore, the above 
results indicated that early-phase circulating miR-1246 was 
an independent predictor for both overall and disease-free 
survival of HCC recipients after liver transplantation.
Oncotarget19826www.impactjournals.com/oncotarget
Figure 1: Identification of differential circulating miRNAs at early-phase after liver transplantation of HCC recipient 
with tumor recurrence by miRNA microarray analysis. A. Significance analysis of microarray (SAM) plot of differentially 
expressed miRNAs. The central solid black line indicates equal expression. The upper and lower grey lines indicate levels for significantly 
altered expression (false discovery rate (FDR) of 0%). The Red dots indicate the identified differential miRNAs. B. Clustering analysis 
of the differential miRNAs between recurrent and non-recurrent HCC recipients. Red indicates high expression and green indicates low 
expression. C. The average expression levels of differential miRNAs in miRNA microarray analysis among healthy donors (n=2), and 
recipients with (n=4) and without (n=8) HCC recurrence. *, P<0.05; **, p<0.01.
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The expression level of circulating miR-1246 
after liver transplantation including early-phase (LT-
2hr), 1 day (LT-Day1) and 1 week (LT-Day7/8) was 
significantly higher than the level in healthy donors and 
before liver transplantation (Figure 5A). The expression 
level of circulating miR-1246 between healthy donors 
and HCC recipients before liver transplantation was 
not statistically significant (Figure 5A). Interestingly, 
among different time points during liver transplantation, 
only the level of circulating miR-1246 at early-phase 
(LT-2hr) revealed a significantly up-regulation in the 
recipients with HCC recurrence compared to that 
Figure 2: Real-time quantitative PCR analysis of 14 differential circulating miRNAs. A. Relative expression levels of the 14 
circulating miRNAs between HCC recipients at early-phase after liver transplantation (LT-2hr) and healthy donors. B. Expression profiles 
of the 14 early-phase circulating miRNAs between recipients with and without HCC recurrence after liver transplantation (LT-2hr). *, 
p<0.05; **, p<0.01; ***, p<0.001.
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without HCC recurrence (Figure 5B). Moreover, 
the expression level of circulating miR-1246 was 
significantly correlated with hepatic miR-1246 at early-
phase after liver transplantation (Figure 5C). There was 
no difference of hepatic miR-1246 between healthy 
donors and HCC recipients before liver transplantation 
(Figure 5D), indicating that circulating miR-1246 was 
not differentially up-regulated in HCC, but induced from 
early-phase after liver transplantation and maintained at 
high level for more than a week.
Figure 3: Receiver Operative Characteristic (ROC) analysis of the sensitivity and specificity analysis of circulating 
microRNAs in predicting HCC recurrence after liver transplantation by A. miR-148a. B. miR-1246. C. miR-1290. D. miR-
148a + miR-1246. AUC, area under curve; *, p<0.05; **, p<0.01 (Asymptotic significance).
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Up-regulation of early-phase miR-1246 
was correlated with liver injury after liver 
transplantation
The level of early-phase circulating miR-1246 was 
positively correlated with the serum AST level from 
day 0 to day 3 after liver transplantation and positively 
correlated with the serum ALT level from day 0 to day 
6 after liver transplantation (Table 4). Moreover, the 
expression level of hepatic miR-1246 at early-phase 
was significantly correlated with serum AST and ALT 
at day 1 and day 2 after liver transplantation (Table 4). 
Furthermore, the expression level of hepatic miR-1246 
was significantly correlated with the expression of tumor 
necrosis factor alpha (TNF-a) mRNA at early-phase 
after liver transplantation (Figure 5E). Collectively, 
these results indicated a positive correlation 
between up-regulation of early-phase miR-1246 and 
increased hepatic injury during acute phase after liver 
transplantation.
Table 1: Summary of Receiver Operating Characteristic (ROC) analyses of clinical factors and early-phase 
circulating miRNAs in predicting HCC recurrence after liver transplantation
ROC analysis of 62 HCC patients
Sensitivity Specificity AUC (95% CI) P value
Clinical factors     
  Milan Criteria 
(Beyond vs within) 77.8% 67.9% 0.729 (0.553 – 0.904) 0.029*
  UCSF criteria 
(Beyond vs within) 66.7% 79.2% 0.730 (0.538 – 0.921) 0.029*
  pTNM stage 
(Advanced vs early) 100% 56.6% 0.717 (0.571 – 0.863) 0.049*
  Pre-OT AFP level 
(≥20ng/ml vs 
<20ng/ml)
55.6% 58.5% 0.570 (0.366 – 0.774) 0.503
  Tumor size (≥5cm 
vs <5cm) 0% 5.7% 0.472 (0.264 – 0.679) 0.798
  Vascular permeation 
(Yes vs no) 62.5% 26.9% 0.678 (0.469 – 0.887) 0.108
  Graft weight to 
recipient ESLV 
(≤60% vs > 60%)
88.9% 69.8% 0.595 (0.411 – 0.780) 0.363
  Type of transplant 
(LDLT vs DDLT) 88.9% 83.0% 0.529 (0.330 – 0.728) 0.780
  Tumor number (>3 
vs ≤3) 44.4% 0.151% 0.647 (0.433 – 0.860) 0.162
  Differentiation 
(Poor vs well) 14.3% 6.0% 0.541 (0.301 – 0.782) 0.782
Early-phase 
circulating miRNAs
    
  miR-148a (High vs 
Low) 88.9% 56.6% 0.727 (0.570 – 0.885) 0.030*
  miR-1246 (High vs 
Low) 88.9% 66.0% 0.775 (0.626 – 0.923) 0.009**
  miR-1290 (High vs 
Low) 66.7% 73.6% 0.701 (0.509 – 0.894) 0.055
  miR-148a + miR-
1246 (Yes vs no) 88.9% 79.2% 0.841 (0.704 – 0.978) 0.001**
*, p<0.05; **, p<0.01.
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Figure 4: Kaplan-Meier plots for early-phase circulating miRNAs that significantly predicted the A. overall survival and 
B. disease-free survival of HCC recipients after liver transplantation.
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Table 2: Summary of Kaplan-Meier analysis of early-phase circulating miRNAs in predicting overall and disease-
free survivals of HCC patients after liver transplantation
miRNAs
Kaplan-Meier analysis of  
Overall survival
Kaplan-Meier analysis of  
Disease-free survival
Log-Rank value P value Log-Rank value P value
Let7C 0.606 0.436 0.646 0.422
miR-21 0.297 0.586 0.395 0.530
miR-23b 1.571 0.210 1.502 0.220
miR-27b 3.448 0.063 3.518 0.061
miR-122 6.505 0.011* 6.984 0.008**
miR-125b 1.757 0.185 2.021 0.155
miR-148a 4.530 0.033* 4.862 0.027*
miR-151p-5p 2.025 0.155 2.012 0.156
miR-192 5.301 0.021* 5.310 0.021*
miR-195 0.381 0.537 0.452 0.502
miR-199a-3p 0.008 0.927 0.063 0.802
miR-215 3.838 0.050* 4.440 0.035*
miR-1246 12.446 0.000*** 12.293 0.000***
miR-1290 6.201 0.013* 6.498 0.011*
*, p<0.05; **, p<0.01; ***, P<0.001.
Table 3: Univariate and multivariate Cox Regression analyses of overall and disease-free survivals of HCC patients 
after liver transplantation
Factors
Overall survival Disease-free survival
Univariate
HR (95% CI) P
Multivariate
HR (95% CI) P
Univariate
HR (95% CI) P
Multivariate
HR (95% CI) P
Sex (Male vs 
Female)
1.57(0.43-
5.72) 0.495 N/A  
1.47(0.40-
5.35) 0.559 N/A  
Age (<=55 yr 
vs <55 yr)
0.67(0.22-
2.06) 0.487 N/A  
0.68(0.22-
2.08) 0.501 N/A  
Serum AFP 
(>20ng/ml vs 
<=20ng/ml)
1.55(0.52-
4.60) 0.433 N/A  
1.55(0.52-
4.61) 0.432 N/A  
Tumor size  
(>5cm vs 
<=5cm)
0.05(0.00-
2884) 0.584 N/A  
0.05(0.00-
2944) 0.585 N/A  
Tumor number  
(>3 vs <=3)
1.86(0.57-
6.05) 0.302 N/A  
1.89(0.58-
6.13) 0.291 N/A  
Vascular 
permeation (Yes 
vs No)
1.76(0.54-
5.77) 0.351 N/A  
1.88(0.57-
6.16) 0.298 N/A  
pTNM stage 
(Advanced vs 
Early)
7.24(0.94-
56.13) 0.058 N/A  
7.46(0.96-
57.79) 0.054 N/A  
(Continued)
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Factors
Overall survival Disease-free survival
Univariate
HR (95% CI) P
Multivariate
HR (95% CI) P
Univariate
HR (95% CI) P
Multivariate
HR (95% CI) P
Differentiation 
(Poor vs Well)
1.34(0.17-
10.60) 0.780 N/A  
1.34(0.17-
10.60) 0.780 N/A  
UCSF criteria 
(Beyond vs 
Within)
2.26(0.76-
6.74) 0.142 N/A  
2.32(0.78-
6.91) 0.130 N/A  
Milan Criteria 
(Beyond vs 
Within)
2.62(0.86-
8.02) 0.091 N/A  
2.76(0.90-
8.45) 0.075 N/A  
Type of LT 
(DDLT vs 
LDLT)
0.95(0.21-
4.29) 0.947 N/A  
0.89(0.20-
3.99) 0.874 N/A  
Graft size 
(>60% vs 
<=60%)
1.27(0.39-
4.12) 0.694 N/A  
1.18(0.36-
3.82) 0.788 N/A  
Let7C (High vs 
Low)
1.55(0.51-
4.75) 0.440 N/A  
1.58(0.52-
4.82) 0.426 N/A  
miR-21 (High 
vs Low)
1.35(0.45-
4.03) 0.587 N/A  
1.42(0.48-
4.22) 0.532 N/A  
miR-23b (High 
vs Low)
2.54(0.56-
11.45) 0.227 N/A  
2.49(0.55-
11.22) 0.236 N/A  
miR-27b (High 
vs Low)
2.90(0.89-
9.43) 0.076 N/A  
2.93(0.90-
9.52) 0.074 N/A  
miR-122 (High 
vs Low)
4.61(1.27-
16.76) 0.020*
7.24(0.56-
93.42) 0.129
4.83(1.33-
17.56) 0.017*
5.47(0.58-
51.77) 0.138
miR-125b 
(High vs Low)
2.18(0.67-
7.07) 0.196 N/A  
2.29(0.71-
7.45) 0.167 N/A  
miR-148a 
(High vs Low)
3.70(1.02-
13.43) 0.047*
0.45(0.03-
6.25) 0.548
3.85(1.06-
14.00) 0.041* 0.43(0.02-7.57) 0.561
miR-151p-5p 
(High vs Low)
2.48(0.68-
9.01) 0.169 N/A  
2.47(0.68-
8.97) 0.170 N/A  
miR-192 (High 
vs Low)
4.93(1.09-
22.27) 0.038*
0.67(0.05-
8.68) 0.760
4.94(1.09-
22.31) 0.038* 0.50(0.03-7.50) 0.618
miR-195 (High 
vs Low)
1.88(0.24-
14.48) 0.544 N/A  
1.99(0.26-
15.28) 0.510 N/A  
miR-199a-3p 
(High vs Low)
1.05(0.34-
3.23) 0.927 N/A  
1.15(0.38-
3.53) 0.803 N/A  
miR-215 (High 
vs Low)
3.06(0.94-
9.97) 0.063 N/A  
3.30(1.02-
10.73) 0.047*
2.13(0.31-
14.71) 0.445
miR-1246 
(High vs Low)
9.32(2.06-
42.19) 0.004**
10.24(1.39-
75.67) 0.023*
9.20(2.04-
41.54) 0.004**
10.12(1.45-
70.47) 0.020*
miR-1290 
(High vs Low)
3.76(1.23-
11.49) 0.020*
0.77(0.20-
3.05) 0.712
3.86(1.26-
11.84) 0.018* 0.88(0.24-3.43) 0.851
*, p<0.05; **, p<0.01.
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Figure 5: The expression analyses of miR-1246 in liver transplantation of HCC recipients and in in vitro models. A. 
The expression profile of plasma miR-1246 of HCC recipients at different time points of liver transplantation. B. Comparison of plasma 
miR-1246 between recurrent and non-recurrent HCC recipients at different time points of liver transplantation. Non-Recur, recipients 
without HCC recurrence; Recur, recipient with HCC recurrence. C. The correlation analysis of early-phase circulating and hepatic miR-
1246 in HCC recipients. D. The expression profile of miR-1246 among tumor and non-tumor liver tissues of HCC patients and healthy 
liver tissues. E. The correlation analysis of early-phase hepatic miR-1246 and TNFa mRNA in HCC recipients. F. The expression level 
of intracellular and extracellular miR-1246 of normal liver cell line in the in vitro simulated ischemia reperfusion model. No extracellular 
level of miR-1246 could be examined because the cells were harvested immediately after ischemia for 2 hours. G. The expression level of 
intracellular and extracellular miR-1246 of normal liver cell line after short-term oxidative stress. H. The expression level of intracellular 
and extracellular miR-1246 in in vitro monocyte-to-M1 macrophage model. *, p<0.05; **, p<0.01; ***, p<0.001; ##, p<0.01(intracellular 
level).
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The source of up-regulation of circulating 
miR-1246
To identify the possible sources of up-regulation 
of circulating miR-1246 at early-phase after liver 
transplantation, different IRI-related in vitro models 
were performed. In the model of in vitro simulated IRI 
model on normal liver cell line, extracellular miR-1246 
was significantly increased from 1 hour to 24 hours after 
IR, but the level of increase was mild (Figure 5F). In the 
in vitro short-term oxidative stress model, administration 
of H2O2 for 2 hours only caused slightly increment of both 
intracellular and extracellular levels of miR-1246 (Figure 
5G). Interestingly, during the course of monocyte-to-M1 
macrophage process, the intracellular and extracellular 
levels of miR-1246 were significantly increased (Figure 
5H). Moreover, the extracellular level of miR-1246 
was increased for more than 10 folds after activation 
or differentiation to M1 macrophage (Figure 5H). We 
also confirmed that TNFa mRNA was up-regulated in 
M1 macrophage (Supplementary Figure S1). The above 
results suggested that activation and differentiation 
of macrophage might be one of the major sources 
contributing to increment of circulating miR-1246 during 
early-phase after liver transplantation.
DISCUSSION
We demonstrated that up-regulation of circulating 
miRNAs during early-phase after liver transplantation 
was associated with late-phase HCC recurrence after liver 
transplantation. We therein identified, for the first time, 
that early-phase circulating miR-148a and miR-1246 were 
potential prognostic biomarkers, achieving high sensitivity 
and specificity, to predict late phase tumor recurrence 
following liver transplantation. Increasing evidences have 
suggested that microRNAs are reliable biomarkers for 
liver diseases and liver transplantation [8, 15]. Most of 
the studies have demonstrated that preoperative miRNAs 
either from recipients’ tissue or serum samples can predict 
HCC recurrence after liver transplantation [12–14]. In 
fact, besides tumor biology, post-liver transplantation 
microenvironment is also critically responsible for 
tumor recurrence after liver transplantation [16]. Our 
previous studies have demonstrated that elevated early-
phase graft injury after liver transplantation can promote 
late-phase tumor progression, invasion and metastasis 
[2, 4], suggesting that post-transplantation early-phase 
graft injury is a critical factor for late-phase HCC 
recurrence after liver transplantation. Agreed with this, 
we therefore provided substantial evidence that early-
Table 4: Pearson correlation analysis of early-phase plasma and hepatic miR-1246 with Aspartate transaminase 
(AST) and Alanine Aminotransferase (ALT) in liver transplantation of HCC patients
    Time points after liver transplantation (Day)
   Pre-LT Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 14
Early-phase 
plasma miR-
1246 level 
(Log2)
Correlation
P
Number
0.007
0.956
62
0.314
0.013*
62
0.259
0.042*
62
0.286
0.025*
61
0.325
0.010*
62
0.249
0.051
62
0.087
0.499
62
0.149
0.249
62
0.142
0.271
62
0.085
0.662
29
AST 
(u/l)
Correlation
P value
Number
-0.035
0.790
62
0.378
0.002**
62
0.341
0.007**
62
0.361
0.004**
61
0.377
0.002**
62
0.388
0.002**
62
0.295
0.020*
62
0.303
0.017*
62
0.241
0.059
62
0.232
0.226
29
ALT 
(u/l)
Early-phase 
hepatic miR-
1246 level 
(Log2)
Correlation
P
Number
-0.093
0.502
54
0.255
0.062
54
0.321
0.018*
54
0.287
0.037*
53
0.168
0.224
54
0.168
0.224
54
0.126
0.362
54
0.108
0.436
54
0.057
0.685
54
0.043
0.843
24
AST 
(u/l)
Correlation
P
Number
-0.069
0.620
54
0.261
0.056
54
0.300
0.028*
54
0.290
0.035*
53
0.245
0.075
54
0.262
0.056
54
0.275
0.044*
54
0.244
0.075
54
0.147
0.290
54
0.253
0.233
24
ALT 
(u/l)
*, p<0.05; **, p<0.01.
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phase circulating miRNAs could be potential biomarkers 
for HCC recurrence after liver transplantation. The 
prediction power of combining early-phase circulating 
miR-148a and miR-1246 was found to be better than 
those pre-transplantation clinical factors in predicting 
HCC recurrence, implying the importance of post-
transplantation early-phase management to prevent tumor 
recurrence of HCC recipients.
So far, there is still lack of effective prognostic 
biomarker for survival of HCC recipients. In our liver 
transplantation center, none of the examined clinical 
variable can significantly predict the overall survival of 
HCC recipients [17]. In this patient cohort, all preoperative 
clinical factors also could not significantly predict the 
survival of HCC recipients after liver transplantation. 
We hypothesized that post-transplantation hepatic injury 
may be an important determinant for the survival of 
HCC recipients. A recent study has demonstrated that 
preoperative tissue miRNAs can predict overall and 
disease-free survival of patients after liver transplantation 
[13], but the relationship between post-operative miRNAs 
and survival rate of HCC recipients is still unknown so far. 
In this study, we observed a positive correlation between 
the up-regulation of early-phase circulating miRNAs and 
poor survival of HCC recipients after liver transplantation. 
Importantly, we discovered early-phase circulating miR-
1246 to be an independent predictor of both overall 
survival and disease-free survival of HCC recipients 
after liver transplantation. Thus, we provided convincing 
evidence for the first time that post-transplantation early-
phase circulating miRNAs could predict the survival of 
HCC recipients after liver transplantation. Indeed, the 
sample size of this study was not statistically sufficient 
especially due to a low sample size in the discovery 
group. The clinical outcomes may be influenced by inter 
biological differences among patients. Further verifications 
of their prediction potentials for HCC recurrence and 
survival after liver transplantation in an increased sample 
size or in other cohorts are necessary.
MiR-1246 is an inducible microRNA responding 
to oxidative stress and immune response [18, 19]. Recent 
studies have reported its potential to be a diagnostic and/
or prognostic biomarker in human cancers [20–23]. MiR-
1246 functionally exhibits a tumor-promoting property in 
some human cancers [24–26]. So far, the roles of miR-
1246 in liver cancer are controversial. One study has 
shown that patients with higher expression level of miR-
1246 are associated with poor disease-free survival after 
chemotherapy and up-regulation of miR-1246 can enhance 
the migration and invasion of HCC cells [27]. In contrast, 
some studies have demonstrated that up-regulation of 
miR-1246 is associated with chemotherapy-induced 
apoptosis in HCC cells [28, 29]. Our results revealed that 
circulating miR-1246 was induced at early-phase after 
liver transplantation. Moreover, the level of early-phase 
circulating miR-1246 was positively correlated with 
serum AST and ALT levels after liver transplantation. 
Furthermore, the expression of hepatic miR-1246 was 
significantly correlated with the serum AST and ALT 
levels as well as the expression of hepatic TNFα mRNA 
at early-phase after liver transplantation. Serum AST 
and ALT level are two well-known indicators of hepatic 
injury. TNFα, a cytokine responded to inflammatory 
stimuli, plays crucial roles in IRI-induced hepatic 
injury [30]. Collectively, our findings indicated that up-
regulation of circulating miR-1246 might be an indicator 
of accelerated hepatic injury during early-phase after 
liver transplantation. Moreover, up-regulation of early-
phase miR-1246 significantly associated HCC recurrence 
after liver transplantation suggested its possible role 
in promoting HCC re-initiation and progression. The 
molecular mechanism of up-regulation of early-phase 
circulating miR-1246 in promoting tumor recurrence is 
needed further characterization.
Hepatic ischemia-reperfusion injury (IRI) is 
the major complication at early-phase after liver 
transplantation [31]. Research evidences have suggested 
that oxidative stress is a major initiator of IRI that triggers 
inflammatory response and cell damage [32]. Enhanced 
inflammatory response is one of the major factors to 
enhance early-phase hepatic injury [16]. Our previous 
study has also demonstrated that increased number of 
infiltrated macrophages is one of the phenomena of 
small-for-size graft injury during early-phase after liver 
transplantation [33]. M1 macrophage which is the major 
type of activated macrophages leading to inflammatory 
response has the characteristic of overexpression of 
TNFα gene [34, 35]. Our data revealed that hepatocytes 
undergone IRI or short-term oxidative stress might not 
be the major contributors to up-regulation of miR-1246 
at early-phase after liver transplantation, while injury-
induced activation and differentiation of macrophage 
(M1 macrophage) might be one of the main sources 
contributing to elevation of circulating miR-1246 at early-
phase after liver transplantation. We postulated that up-
regulation of miR-1246 was positively associated with 
increased inflammatory response during early-phase 
after liver transplantation. In addition to that elevated 
expression of serum miR-148a is positively associated 
with liver injury after liver transplantation [15], our study 
thus provided important evidences that hepatic injury-
induced miRNAs could also play important roles in late-
phase tumor recurrence.
In conclusion, our study demonstrated that early-
phase circulating miR-148a and miR-1246 were potential 
biomarkers in predicting HCC recurrence after liver 
transplantation. Early-phase circulating miR-1246 was 
not only a biomarker for acute hepatic injury but also a 
novel prognostic biomarker of poor overall and disease-
free survival of HCC recipients after liver transplantation.
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MATERIALS AND METHODS
Patients and clinical samples
Sixth-two HCC patients received liver 
transplantation from Oct 2003 to May 2010 in Queen Mary 
Hospital, Department of Surgery, the University of Hong 
Kong, were included in this study. The number of patients 
in this study represented about 54.4% of the total number 
of HCC patient (114) undergone liver transplantation 
during these years. The last follow-up date of the patients 
was in March 2015. Among them, 9 HCC recipients were 
found to have recurred tumor after liver transplantation. 
The clinical information between recurrent and non-
recurrent patients was summarized in Supplementary Table 
S2. Sixty-two plasma samples and 55 liver tissues were 
collected from the HCC recipients at 2 hours after portal 
vein reperfusion during liver transplantation (LT-2hr). 
Thirty-three, 36 and 38 plasma samples were collected 
from the HCC recipients at pre-liver transplantation (pre-
LT), 1 day after liver transplantation (LT-1Day) and 1 
week after liver transplantation (LT-1Week) respectively. 
Plasma and liver tissues from 12 healthy donors were 
included for normal control. To investigate the expression 
of hepatic miR-1246 in HCC, 35 pairs of tumor and non-
tumor liver tissues from the HCC patients underwent 
hepatectomy were also recruited. The human ethics of 
the study has been approved by the Institutional Review 
Board (IRB, Ref. No.:UW_11-099). The consent forms 
were obtained from all the donors and recipients involved.
Cell lines
Human normal liver cell line (MIHA) and human 
monocytic cell line (THP-1) were purchased from American 
Type Cell Culture (Manassas, USA) and maintained in the 
optimal medium according to the instruction.
RNA isolation
Total RNAs including small RNAs were extracted 
from the plasma of patients or the media of cells using 
miRNeasy Mini Kit (Qiagen) according to manufacturer’s 
instruction. Total RNAs in liver tissues or cell lines were 
extracted by TriZol reagent (Life Technologies) according 
to manufacturer’s instruction.
MicroRNA microarray profiling
MicroRNA microarray analyses were performed 
among the plasma of healthy donors (n=2) and early-phase 
(LT-2hr) plasma of HCC recipients with (n=4) and without 
(n=8) tumor recurrence after liver transplantation. Each of 
100 ng of plasma RNA was labeled with Cy-3 fluorescent 
dye and performed miRNA profiling using Agilent Human 
miRNA Microarray Kit (V2) (Agilent Technologies, 
USA). The array contains 723 human and 76 viral miRNA 
probes. The slide was scanned by the Agilent Microarray 
Scanner. After filtering the non-expressed probes and 
normalization by 75% percentile shift method, the miRNA 
data was analyzed by GeneSpring software (Agilent 
Technologies).
Real-time quantitative RT-PCR
The expression levels of miRNAs were determined 
by TaqMan real-time quantitative PCR (TaqMan 
MicroRNA Assays, Life Technologies) and normalized 
to the level of U6 Small Nuclear 2 (RNU6B, Assay 
ID:001973) using a 7900HT PCR machine (Life 
Technologies) according to the manufacturer’s protocol. 
Probes for Let7C(000379), miR-21(000397), miR-
23b(000400), miR-27b(000409), miR-122(002245), 
miR-125b(000449), miR-148a(000470), miR-151-
5p(002642), miR-192(000491), miR-195(000494), 
miR-199a-3p(002304), miR-215(000518), miR-
1246(462575_mat) and miR-1290(002863) were 
purchased from Life Technologies company. 
The relative expression level of miRNA for each 
sample was calculated as: ΔΔCt(miRNAsample)= 
ΔCt(miRNAcalibrator)-ΔCt(miRNAsample), where ΔCt(m
iRNAcalibrator)=Ct(miRNAcalibrator)-Ct(RNU6Bcalibrator); 
ΔCt(miRNAsample)=Ct(miRNAsample)-Ct(RNU6Bsample). 
The calibrator was defined as the sample with the highest 
Ct value of miRNA (sample with the lowest expression 
level of miRNA) among all samples [36]. The relative 
expression level of miRNA was presented in log2 base. 
For in vitro experiments, the expression level of miR-
1246 was determined as fold difference to untreated 
cells using 2-ΔΔCt method. The expression level of TNFα 
mRNA in the samples was analyzed by quantitative RT-
PCR (Life Technologies) as described previously [36, 37]. 
The gene encoding beta-actin was used as internal control. 
Primers used were as follows: for TNFα, forward:5’-
GCCCATGTTGTAGCAAACCC-3’, reverse:5’-
GGTTATCTCTCAGCTCCACGC-3’; for beta-actin, 
forward:5’-CTCTTCCAGCCTTCCTTCCT-3’, reverse:5’-
AGCACTGTGTTGGCGTACAG-3’. All reactions were 
performed in duplicate.
In vitro simulated ischemia-reperfusion model
To investigate whether hepatic ischemia-reperfusion 
injury might lead to increased secretion of miR-1246 from 
hepatocytes, the in vitro simulated ischemia reperfusion 
model [38] was employed on MIHA. To generate ischemic 
effect on cells, 100% mineral oil was applied to cover the 
cells for 2 hours. Then the mineral oil was removed and 
replenished with fresh media. Media and cells from different 
time points after reperfusion (Cells: 0, 1, 2, 4 and 24 hours; 
Media: 1, 2, 4, and 24 hours) were collected for analysis of 
the expression of miR-1246 by real time quantitative RT-
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PCR. The experiment was repeated for three times. P<0.05 
was considered as statistical significance.
In vitro short-term oxidative stress model
To investigate whether accelerated oxidative stress 
during early-phase of liver transplantation might cause 
induction of miR-1246 from hepatocyte, we generated a 
short-term oxidative stress on the normal liver cell line, 
MIHA. Briefly, MIHA cells were incubated with different 
concentrations of H2O2 (0, 0.5, 1, 2, 5 and 10mM) for 2 
hours. RNAs from media and cells were extracted for 
analysis of the expression of miR-1246 by real-time 
quantitative RT-PCR. The experiment was repeated 
for three times. P<0.05 was considered as statistical 
significance.
In vitro monocyte-to-M1 macrophage model
To investigate whether increased inflammation 
response might increase the level of miR-1246, we 
performed an in vitro monocyte-to-M1 macrophage model 
[35, 39]. Briefly, the THP-1 cells were activated by treating 
with phorbol myristate acetate (PMA) from 1 hour to 24 
hours. Differentiation of THP-1 derived M1 macrophage 
was started after 6-hr treatment of PMA. The THP-1 cells 
were polarized to M1 macrophage by incubation with 25 
ng/ml of interferon gamma (IFN-γ, Life Technologies) 
and 150 ng /ml of lipopolysaccharide (LPS; Sigma) for 
18 hours. Cells and media were collected for analysis of 
miR-1246 expression by real-time quantitative RT-PCR. 
The experiment was repeated for three times. P<0.05 was 
considered as statistical significance.
Statistical analysis
The expression levels of circulating miRNAs 
in clinical samples were graphed by Prism Version 
5.01 (Graphpad). Statistical analyses were performed 
by SPSS software version 20 (SPSS, Chicago, IL). 
Categorical variables were analyzed by Chi-square test 
or Fisher’s exact test, while continuous variables were 
analyzed by Mann-Whitney U test. The correlations 
of differential circulating miRNAs to clinical factors 
were analyzed by Pearson correlation analysis. To 
examine the prognostic value of miRNAs, Receiver 
Operating Characteristic (ROC) curve was generated 
for each miRNA in predicting tumor recurrence after 
liver transplantation. The optimal cut-off value for 
each miRNA was obtained from Youden index. The 
sensitivity and specificity of miRNA to predict HCC 
recurrence after liver transplantation was determined 
by ROC analysis. Kaplan-Meier analysis applying log-
rank test was performed to analyze the prognostic value 
of each miRNA in predicting overall and disease-free 
survival of HCC recipients after liver transplantation. 
Univariate Cox-regression analysis was performed 
to examine the hazard ratio of miRNAs and clinical 
factors in predicting overall and disease-free survival of 
HCC recipients. Multivariate Cox-regression analysis 
was performed to compare the significant factors 
in univariate cox-regression analysis. P<0.05 was 
considered as statistically significant.
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